기관지확장증 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Bronchiectasis Market Outlook

Thelansis's "Bronchiectasis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchiectasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchiectasis Overview

Bronchiectasis is a chronic, progressive respiratory disorder characterized by irreversible dilation of the bronchi, resulting from persistent infection and inflammation that damage airway structure. The disease is broadly classified into cystic fibrosis (CF)-related and non-cystic fibrosis bronchiectasis (NCFB), with the latter accounting for the majority of cases and arising from diverse etiologies including prior infections (e.g., tuberculosis, pneumonia), immunodeficiency, autoimmune diseases, and impaired mucociliary clearance. The underlying pathophysiology is driven by a vicious cycle of impaired mucus clearance, chronic bacterial colonization-most commonly Pseudomonas aeruginosa and Haemophilus influenzae-and sustained neutrophilic inflammation. This cycle leads to progressive lung damage, declining pulmonary function, and increased susceptibility to recurrent exacerbations.

Clinically, patients present with chronic productive cough, frequent exacerbations, dyspnea, and fatigue, resulting in significant impairment in quality of life. Despite increasing disease recognition and burden, therapeutic options remain limited and largely symptomatic, including airway clearance techniques, antibiotics, and supportive care. The treatment landscape is evolving, with ongoing research focused on inhaled antibiotics, mucoactive agents, and anti-inflammatory therapies aimed at breaking the cycle of infection and inflammation and improving long-term outcomes.

Key Highlights

• In Germany, diagnosed prevalent cases are projected to increase from 44.9K in 2025 to 48.1K by 2035, reflecting steady growth (0.7% CAGR).
• The disease is characterized by recurrent exacerbations and chronic infection, contributing to progressive lung function decline and high healthcare burden.
• Limited availability of disease-modifying therapies highlights a significant unmet need, with increasing focus on inhaled antibiotics and anti-inflammatory agents.

Market Overview

• The Germany bronchiectasis market is projected to grow from $108M in 2025 to $167M by 2035, reflecting moderate-to-strong growth driven by improved diagnosis and emerging therapies.
• Market expansion is supported by:
• Increasing adoption of inhaled antibiotics and chronic management therapies
• Rising awareness and diagnosis of NCFB
• Despite moderate patient growth (0.7% CAGR), market value is driven by chronic treatment use and management of recurrent exacerbations.
• Future growth will depend on the development of targeted therapies that address underlying inflammation and infection, improving disease control and reducing exacerbation frequency.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• GlaxoSmithKline
• AstraZeneca
• CSL Behring
• S-INFINITY Pharmaceuticals Co., Ltd
• Shanghai Huilun Pharmaceutical Co., Ltd.
• Boehringer Ingelheim
• Haisco Pharmaceutical Group Co., Ltd.
• Thirty Respiratory Limited
• Genentech, Inc.
• Verona Pharma plc
• Sanofi
• Chiesi Farmaceutici S.p.A.
• Armata Pharmaceuticals, Inc.
• Renovion, Inc.
• Insmed Incorporated
• Reistone Biopharma Company Limited

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)